These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30926528)

  • 41. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.
    Dai H; Zhu Y; Chen Z; Yan R; Liu J; He Z; Zhang L; Zhang F; Yan S
    Endokrynol Pol; 2023; 74(3):234-242. PubMed ID: 37335067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.
    Wang X; Wen D; Chen Y; Ma L; You C
    Cardiovasc Diabetol; 2022 Jun; 21(1):107. PubMed ID: 35706032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?].
    Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M
    Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.
    Dicembrini I; Giannini S; Ragghianti B; Mannucci E; Monami M
    J Endocrinol Invest; 2019 Sep; 42(9):1029-1039. PubMed ID: 30762200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels.
    Cao YX; Liu HH; Li S; Li JJ
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):87-97. PubMed ID: 30229525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience.
    Farnier M
    Curr Opin Lipidol; 2016 Dec; 27(6):597-604. PubMed ID: 27755114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis.
    Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
    Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
    Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
    Bittner VA; Giugliano RP; Brinton EA; Guyton JR
    J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PCSK9 inhibitors and managing cost in the managed care setting.
    Stadler SL; Cook TJ
    Am J Manag Care; 2017 Jun; 23(9 Suppl):S149-S155. PubMed ID: 28978220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.
    Ge X; Zhu T; Zeng H; Yu X; Li J; Xie S; Wan J; Yang H; Huang K; Zhang W
    Biomed Res Int; 2021; 2021():8032978. PubMed ID: 34754882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study.
    van Bruggen FH; Zuidema SU; Luijendijk HJ
    BMC Med Res Methodol; 2024 Jun; 24(1):137. PubMed ID: 38909176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.